Diminished Renal Function and the Incidence of Heart Failure

Johan Ärnlöv*

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, and the Department of Health and Social Sciences, Högskolan Dalarna, Falun, Sweden

Abstract: Heart failure is one of the most common, costly, disabling and deadly diseases. During the last decade, several different indices reflecting renal function such as creatinine-based glomerular filtration rate, circulating levels of cystatin C and low-grade albuminuria have been demonstrated to be independent risk factors for heart failure. This review summarizes our current knowledge of the relationship between diminished renal function and the incidence of heart failure in the community, and also in individuals with increased risk of heart failure such as patients with overt cardiovascular disease, hypertension or diabetes. This review will also put forward important areas of future research in this field.

Keywords: Heart failure, kidney disease, glomerular filtration rate, creatinine, cystatin C, albuminuria.

INTRODUCTION

There is growing recognition of the clinical importance of the symbiotic relationship between the kidney and the heart (Fig. 1) [1]. It is well known that patients with heart failure often also develop renal failure, and renal impairment in heart failure patients has become increasingly recognized as an independent risk factor for morbidity and mortality [2-9]. A recent meta-analyses by Smith and co-workers [10] showed that a large proportion of heart failure patients had renal impairment of some degree, and that these patients had a 50% increased relative risk for mortality compared to heart failure patients with normal renal function. Moreover, almost a third of heart failure patients had moderate to severe renal impairment, with a more than 2-fold increased relative mortality risk and greater than 50% mortality during five years of follow-up.

The temporal relationship between heart failure and renal failure appears to be complex, however, and the opposite chain of events is also common: patients with chronic kidney disease are at substantially higher risk of developing cardiovascular disease and heart failure. In fact, heart failure is about 15 times more common in patients with chronic kidney disease than in patients with normal renal function [11] and individuals with chronic kidney disease are more likely to die of cardiovascular disease than to develop end-stage renal disease [12, 13].

Although the close relationship between cardiovascular and renal pathologies is well recognized in advanced nephropathy and heart failure, it has received less attention in early disease. To date, several studies have suggested that diminished renal function may be involved in the development of heart failure at an early stage, prior to the development of clinically overt heart failure and kidney disease. The present review will focus on studies that have reported the longitudinal relationship between different indices of renal function (serum creatinine, creatinine-based equations of glomerular filtration rate, serum cystatin C, and albuminuria) and the development of heart failure in individuals without heart failure at baseline.

SERUM CREATININE AND CREATININE-BASED EQUATIONS OF GLOMERULAR FILTRATION RATE AS RISK FACTORS FOR INCIDENCE OF HEART FAILURE

The serum levels of creatinine and creatinine-based equations of glomerular filtration rate have been used extensively in clinical practice, as well as in research, as indirect estimates of glomerular filtration rate. Although widely used, creatinine-based equations of glomerular filtration rate such as Cockcroft-Gault [14] or the Modification of Diet in Renal Disease (MDRD) equation [15] have been shown to have limitations as estimates of glomerular filtration rate, particularly in the elderly and in individuals with glomerular filtration rate in the normal or near-normal range [16].

Community-Based Studies

The association between elevated serum levels of creatinine and the incidence of heart failure in the community was first reported by Gottdiener and co-workers in the Cardiovascular Health Study [17]. In that investigation in an elderly study population, a comprehensive evaluation of different risk factors for heart failure was performed and serum levels of creatinine were suggested to contribute to 6% of the attributable risk of heart failure [17]. In a more recent report from the Cardiovascular Health Study, Fried and colleagues concluded that even in a sub-sample of healthy individuals and individuals with mild renal impairment (defined as serum creatinine >1.5 mg/dL), elevated serum creatinine was associated with an increased risk of heart failure [18]. The association between creatinine-based glomerular filtration rate and incidence of heart failure has since been validated in another cohort of elderly (the EPESE-study) [19] as well as in a cohort with a wider age range (the ARIC study) [20].
High-Risk Populations

Serum creatinine levels as a predictor of heart failure has also been evaluated in individuals with high risk of heart failure such as patients with prevalent cardiovascular disease, hypertension, and/or diabetes. In most of these studies [21-23], however, heart failure has not been evaluated as the primary outcome. For instance, in secondary analyses of the Heart Outcomes and Prevention Evaluation (HOPE) study, mild renal insufficiency was associated with a doubled risk of heart failure in crude analyses but not after adjusting for other cardiovascular risk factors [21]. In the Valsartan in Acute Myocardial Infarction Trial (VALIANT) involving patients with an acute myocardial infarction[22], lower glomerular filtration rate (MDRD) was associated with a higher risk of heart failure in crude analyses. No multivariable analyses were presented in that study. Moreover, a comparison of the predictive value of two different creatinine-based equations for glomerular filtration rate (Cockcroft-Gault and MDRD) was performed in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. Interestingly, in that study estimated glomerular filtration rate according to MDRD was a strong predictor of future heart failure events while estimated creatinine clearance from Cockcroft-Gault was not [23].

In a report from the Heart and Estrogen/Progestin Replacement Study (HERS), the primary aim was to identify predictors of heart failure in post-menopausal women with coronary heart disease [24]. Bibbins-Domingo and co-workers reported that diabetes was the strongest risk factor for heart failure and that diabetic women with depressed creatinine clearance were those with the highest risk. The relevance of impaired renal function in individuals with diabetes is further supported by another study in men and women with diabetes, in which those with diabetic nephropathy were at increased risk of subsequent heart failure [25]. Importantly, in a post-hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, patients with diabetes and more severe chronic kidney disease had higher incidence of heart failure, a trend that was reduced by treatment with losartan, an angiotensin receptor blocker [26].

CYSTATIN C, A SUPERIOR RISK MARKER FOR INCIDENCE OF HEART FAILURE?

Circulating cystatin C concentration is a relatively novel measure of kidney function that has been suggested to overcome many of the limitations of using creatinine-based estimates, as the relationship between kidney function and cystatin C concentration does not appear to vary with age, sex, and body mass [16, 27, 28]. Recently, cystatin C has been suggested to be a more reliable indicator of kidney function than creatinine-based glomerular filtration rate, particularly in the elderly and in individuals with glomerular filtration rate within the normal range [16, 29, 30]. It should, however, be noted that the superiority of cystatin C is not undisputed, and it is yet to be fully established as the marker of choice for glomerular filtration rate in clinical practice [31].

Community-Based Studies

The association between serum cystatin C and development of heart failure in the community was first reported by Sarnak and co-workers in the Cardiovascular Health Study [32]. Serum cystatin C concentrations were associated with a linear increase in risk across quintiles of cystatin C, in contrast to serum creatinine concentration or estimated GFR where there was a J-shaped association with heart failure. This study suggested that serum cystatin C concentrations provide a better measure of risk assessment than serum creatinine concentrations, particularly in the “normal” range of kidney function. This was further supported by a subsequent report from the Cardiovascular Health Study, where Shlipak and co-workers showed that higher serum concentrations of cystatin C independently predicted heart failure also in individuals without chronic kidney disease while creatinine-based glomerular filtration rate equations (MDRD) did not [33].

In secondary analyses in the Cardiovascular Health study, slightly stronger associations between cystatin C levels and heart failure were seen in blacks as compared to whites [32]. The question of ethnic differences in the association between renal impairment and the development of heart failure was investigated in greater depth by Bibbins-Domingo in the Health, Aging, and Body Composition Study [34]. In that study, the association between renal function and heart failure risk was stronger in older black individuals than in older white individuals, and this difference was particularly evident when cystatin C concentration was used to assess renal function. In fact, the population attributable risk of heart failure was 47% for blacks with moderate or high concentrations of cystatin C but only 5% in whites [34].

In a recent report from the Physicians’ Health study, Djousse and co-workers demonstrated that higher levels of cystatin C were associated with an increased risk of heart
failure and that this association was evident in hypertensive individuals only [35]. This result differs from other community-based samples, where no interaction regarding hypertensive status has been reported.

One major limitation of most studies investigating the relationship between renal impairment and incidence of heart failure has been the lack of differentiation between systolic and diastolic heart failure. This important issue was recently addressed by Moran and co-workers in another report from the Cardiovascular Health Study [36] In that study, cystatin C levels were linearly associated with the incidence of systolic heart failure, whereas only the highest concentrations of cystatin C were predictive of diastolic heart failure [36], suggesting that there may be somewhat different pathophysiological pathways leading to these two types of heart failure.

High-Risk Populations

Several previous studies have indicated that elevated cystatin C levels are predictive of cardiovascular morbidity and mortality in patients with prevalent coronary heart disease [37, 38], yet the association between cystatin C levels and the risk of heart failure in high-risk populations has been less studied. In a report from the Heart and Soul Study involving ambulatory patients with coronary heart disease, higher cystatin C levels were found to predict incident heart failure [39]. Interestingly, high cystatin C levels had similar predictive value for adverse clinical outcomes in individuals with or without microalbuminuria, suggesting that the association between higher cystatin C concentrations and risk of heart failure is not solely mediated by microalbuminuria.

LOW-GRADE ALBUMINURIA AND THE INCIDENCE OF HEART FAILURE

Although low-grade albuminuria has traditionally been considered to be an indicator of early renal pathology, there is an emerging view that albuminuria is also a marker of generalized vascular pathology such as endothelial dysfunction (the STENO hypothesis)[40]. Many prospective studies have suggested that increased risk of cardiovascular events begins well below the current threshold of microalbuminuria [41, 42], yet the association with heart failure has been less studied.

Community-Based Studies

There have been a few community-based studies investigating the relationship between albuminuria and incidence of heart failure. In a study by Kistorp and co-workers [43], an increased urinary albumin/creatinine ratio was not found to be predictive of incidence of heart failure in a Danish cohort. It should be noted that in that study, incidence of heart failure was considered a secondary endpoint, and there was only a low number of heart failure events during follow-up (n = 19).

In contrast, Ingelsson et al. reported that the urinary albumin excretion rate predicted heart failure incidence independently of both established risk factors for heart failure and other indices of renal function (creatinine-based glomerular filtration rate (MDRD) and serum cystatin C) in a community-based sample of elderly men (the Uppsala Longitudinal Study of Adult Men, ULSAM)[44]. Furthermore, urinary albumin excretion rate also remained an independent predictor of heart failure incidence in a sub-sample without myocardial infarction (either at baseline or during follow-up), suggesting that the rate of excretion of urinary albumin also predicts the incidence of non-ischemic heart failure.

High-Risk Populations

Several authors have reported an association between albuminuria and heart failure in patients with diabetes. For instance, in the Appropriate Blood Pressure Control in Diabetes (ABCD) trial, patients with type 2 diabetes and macroalbuminuria were found to have a greater than threefold risk of heart failure compared to diabetics with normo- or microalbuminuria [45]. Moreover, in the DIABHYCAR study (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril), every 10-fold increase in urinary albumin concentration was associated with a more than doubled risk [46]. In two reports from the HOPE study, in patients either with diabetes or without diabetes, microalbuminuria [47] or any degree of albuminuria [42] was found to be predictive of heart failure, independently of established cardiovascular risk factors (including serum creatinine)[42].

The predictive importance of low-grade albuminuria in hypertensive individuals with left ventricular hypertrophy was shown in the LIFE study [48], where a urinary albumin/creatinine ratio of > 3.5 mg/mmol was associated with a twofold higher risk of future heart failure. In that study, the participants with both albuminuria and ECG strain were at particularly high risk.

It is important to note that although there are convincing data to show that low-grade albuminuria is an independent predictor of heart failure, this association should not necessarily be construed to imply that there is a direct benefit in lowering of the albuminuria level. This essential issue was addressed in the landmark study by deZeeuw and co-workers in a report from the RENAAL trial. In that study, low-grade albuminuria was found to be an independent predictor of future heart failure in individuals with diabetic nephropathy, but more importantly, a 50% reduction in albuminuria after 6 months of antihypertensive treatment was associated with a 27% reduction in heart failure risk, supporting the idea of lowering of albuminuria as a treatment goal in order to achieve cardiovascular protection [49].

THE CONJOINT EFFECT OF GLOMERULAR FILTRATION RATE AND ALBUMINURIA FOR THE PREDICTION OF HEART FAILURE

Even though several previous studies have shown that indices of glomerular filtration rate and albuminuria predict heart failure independently of each other, the conjoint effect of glomerular filtration rate and albuminuria for the prediction of heart failure is less reported. In a secondary analysis in the Cholesterol And Recurrent Events (CARE) trial [50], myocardial infarction patients with both proteinuria and impaired glomerular filtration rate (< 60 mL/min/1.73 m2)
were more than twice as likely to develop heart failure as patients with one abnormality, or with neither.

**FUTURE RESEARCH**

Despite the relatively large number of studies, several important issues regarding the prognostic value of the indices of renal dysfunction and the development of heart failure remain unresolved. First, there have been no studies evaluating whether adding the indices of diminished renal function to a model with established risk factors for heart failure will improve the model discrimination, calibration, and global model fit for the prediction of heart failure [51-54]. It is essential that this issue be addressed in order for these indices to be used in clinical practice, to identify individuals who have an elevated risk of heart failure. Second, no ideal cut-offs for the indices of renal impairment have been identified. The thresholds used have either been based on classification of renal disease or on the distribution of the variable of interest in a particular sample. Future studies must identify relevant thresholds for the different renal indices in order to achieve optimal model discrimination. Thirdly, whether or not the conjoint effect of glomerular filtration rate and albuminuria conveys additional prognostic information has not been well studied. Fourthly, it is important to note that heart failure was not the primary outcome in most studies in high-risk populations. Fifth, most community-based studies were mainly performed in samples taken from the elderly and our knowledge of the predictive capacity of the indices of renal function is limited in individuals who are less than 65 years old. Sixth, patients with renal dysfunction are often excluded from intervention trials and our knowledge of whether intervention is beneficial in this patient group is limited. There is a need for more studies that evaluate the benefit of improvement of renal function in lowering the risk of heart failure. Finally, there have been few data on the prediction of different subtypes of heart failure such as diastolic heart failure and non-ischemic heart failure.

**CONCLUSIONS**

There is a considerable body of data to support the notion that diminished renal function, as evaluated by reduced glomerular filtration rate or low-grade albuminuria, is an independent risk factor for subsequent heart failure both in high risk populations such as patients with overt cardiovascular disease, hypertension or diabetes, and in the community. Cystatin C appears to be a superior marker for future risk of heart failure compared to serum levels of creatinine or creatinine-based equations of glomerular filtration rate. Moreover, the risk of heart failure appears to begin at levels of glomerular filtration rate and albuminuria that are considered to be in the normal range according to current clinical practice. Some data suggest that the relative importance of renal dysfunction for the development of heart failure is different in different ethnic groups, an issue that merits further studies. Thus, based on the studies presented in this review, the close association between renal and cardiac dysfunction already appears to be present before the development of clinically overt renal and cardiovascular disease, an observation that challenges the current definition of cardiorenal syndrome [1].

**SOURCES OF SUPPORT**

The Swedish Research Council (2006-6555) and the Swedish Heart-Lung Foundation. There are no conflicts of interest.

**REFERENCES**

[1] Ronco C, House AA, Haapio M. Cardiorenal syndrome: Refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34(5): 957-62.

[2] Hillege HL, Gribes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-10.

[3] Hillege HL, Nitsch D, Pfeiffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-8.

[4] Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 2004; 44: 193-9.

[5] Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: Evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004; 15: 2195-203.

[6] Smith GL, Shlipak MG, Havranek EP, et al. Race and renal impairment in heart failure: Mortality in blacks versus whites. Circulation 2005; 111: 1270-7.

[7] Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmaceutical therapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587-92.

[8] McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-9.

[9] van de Wal RM, Asselbergs FW, Plokker HW, et al. High prevalence of microalbuminuria in chronic heart failure patients. J Card Fail 2005; 11: 602-6.

[10] Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-96.

[11] Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004; 13: 163-70.

[12] Sarnak MJ, Levey AS, Schoeller B, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003; 42: 1050-65.

[13] Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006; 17: 2034-47.

[14] Cockerd DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

[15] Levey AS, Bosch JP, Lewis JB, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-70.

[16] Fiser D, Ritz E. Serum cystatin c concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79-83.

[17] Gottlieber JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly. The cardiovascular health study. J Am Coll Cardiol 2000; 35: 1626-37.

[18] Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: 1364-72.

[19] Chae CU, Albert CM, Glynn RJ, Guralnik JM, Cushman GC. Mild renal insufficiency and risk of congestive heart failure in men and women > =70 years of age. Am J Cardiol 2003; 92: 682-6.

[20] Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (arc) study. J Am Soc Nephrol 2007; 18: 1307-15.

[21] Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the
Diminished Renal Function and the Incidence of Heart Failure

impact of ranipril: The hope randomized trial. Ann Intern Med 2001; 134: 629-36.

[22] Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcome after myocardial infarction. N Engl J Med 2004; 351: 1285-95.

[23] Ruilope LM, Zanchetti A, Julius S, et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertensive population of the value trial. J Hypertens 2007; 25: 1473-9.

[24] BIBbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary artery disease. Circulation 2004; 110: 1424-30.

[25] Bertoni AG, Hundleby MG, Massing MW, Bonds DE, Burke GL, Goff DC Jr, Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.

[26] Remuzzi G, Ruggenenti P, Perna A, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the renal trial results. J Am Soc Nephrol 2004; 15: 3117-25.

[27] KEEVIL BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin c: Implications for the assessment of glomerular filtration rate. Clin Chem 1998; 44: 1535-9.

[28] Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin c measured by automated immunoassay: A more sensitive marker of changes in glt than serum creatinine. Kidney Int 1995; 47: 312-8.

[29] Levey AS, Coresh J, Greene T, et al. Estimating the glomerular filtration rate: A new equation. Clin Chem 2006; 52: 266-74.

[30] Laterza OF, Price CP, Scott MG. Cystatin c: An improved estimator of glomerular filtration rate? Clin Chem 2002; 48: 699-707.

[31] Massey D. Commentary: Clinical diagnostic use of cystatin c. J Clin Lab Anal 2004; 18: 55-60.

[32] Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin c concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142: 497-505.

[33] Shipkag MG, Katz R, Estacio RO, Mehler P. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: The whoop study. Ann Intern Med 2005; 112: 969-75.

[34] Bibbins-Domingo K, Chertow GM, Fried LF, et al. Serum cystatin c and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-46.

[35] Djoos L, Kurth T, Gaziano JM. Cystatin c and risk of heart failure in the physicians' health study (phs). Am Heart J 2008; 155: 82-6.

[36] Moran A, Katz R, Smith NL, et al. Cystatin c concentration as a predictor of systolic and diastolic heart failure. J Card Fail 2008; 14: 19-26.

[37] Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin c: A novel predictor of outcome in suspected or confirmed non-st-elevation acute coronary syndrome. Circulation 2004; 110: 2342-48.

[38] Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin c in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 2005; 51: 321-7.

[39] Is JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin c with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the heart and soul study. Circulation 2007; 115: 173-9.

[40] Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kobold-Envelosen A. Albuminuria reflects widespread vascular damage. The steno hypothesis. Diabetologia 1989; 32: 219-26.

[41] Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham heart study. Circulation 2005; 112: 969-75.

[42] Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.

[43] Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, c-reactive protein, and uramin albumin levels as predictors of mortality and cardiovascular events in older adults. Jama 2005; 293: 1609-16.

[44] Ingelsson E, Sundstrom J, Lind L, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J 2007; 28: 1739-45.

[45] Hockenmuth ML, Estacio RO, Mehler P, et al. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail 2004; 10: 126-31.

[46] Vaur L, Gueret P, Lievre M, Chabaud S, Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: Observations from the diabycar study. Diabetes Care 2003; 26: 855-60.

[47] Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the heart outcomes prevention evaluation (hope) study. Circulation 2003; 107: 1284-90.

[48] Okin PM, Wachthell K, Devereux RB, et al. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: The ePHore study. Am J Hypertens 2008; 21: 273-9.

[49] de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-7.

[50] Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: Analysis of a previously conducted randomised trial. BMJ 2006; 332: 263.

[51] Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-35.

[52] Pencina MJ, D'Agostino RB S, D'Agostino RB J, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the roc curve to reclassification and beyond. Stat Med 2007; 26: 959-75.

[53] Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882-90.

[54] Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006; 355: 2615-7.